Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Dyne’s FORCE RNA therapy reversed muscle damage in mice, and its first FSHD trial is now cleared
DYNE-302 enters clinical development after FDA clearance as Dyne expands its FORCE pipeline following a $431.4 million equity raise.
Altimmune’s $535m balance sheet backs new pemvidutide alcohol use disorder pathway
Pemvidutide reduced heavy drinking in Phase 2, opening a new market for Altimmune as investors weigh cash, dilution and Phase 3 risks.
Sleep apnoea biotech Apnimed (APMD) climbs in Nasdaq debut after upsized offering
Apnimed raised $192M in an upsized Nasdaq IPO to fund oxnimbi's launch, with the FDA's February 28, 2027 decision on the first oral OSA pill now the pivot.
Phase 3 hepatitis C win fails to lift Atea stock against Gilead’s Epclusa
Atea’s eight-week hepatitis C regimen met Phase 3 endpoints against Epclusa, but $AVIR fell as investors questioned its commercial edge.
![Ratio Therapeutics’ $70 million Series C financing will support the ATLAS trial of [Ac-225]RTX-2358, expand its targeted radiotherapeutics pipeline and strengthen radiopharmaceutical manufacturing capacity. Representative image.](https://business-news-today.com/wp-content/uploads/2026/07/Ratio-Therapeutics-raises-70-million-to-advance-ATLAS-trial-and-radiopharmaceutical-manufacturing-380x280.png)
Can Ratio Therapeutics turn a $70m funding round into a scalable cancer-treatment platform?
Ratio Therapeutics’ Series C financing gives the Boston oncology company additional capital to advance [Ac-225]RTX-2358, bring another radioligand therapy into clinical development and expand the manufacturing network needed to support a broader cancer pipeline.
Samsung Biologics is not just buying PolyPeptide. It is buying into the GLP-1 supply chain
Samsung Biologics plans to acquire PolyPeptide for CHF 1.46 billion. Read how the deal targets peptide CDMO capacity and GLP-1 manufacturing demand.
Why argenx is buying Forte Biosciences before FB102 enters its bigger proof stage
argenx agrees to buy Forte Biosciences for $2.2 billion. Read how FB102 could reduce Vyvgart concentration risk and reshape ARGX’s autoimmune strategy.
CMP-002 trial clearance unlocks $50m as CAMP4 enters first-in-human stage
CAMP4 unlocks up to $50 million after Australian clearance for its CMP-002 trial, strengthening runway while creating major dilution.
GSK Q2 2026 core operating profit rises 7% on specialty medicines strength
GSK Q2 core operating profit rose 7% to ÂŁ2.8bn, but a ÂŁ1.3bn camlipixant hit and 2028-2030 dolutegravir cliff frame the ÂŁ40bn 2031 sales delivery test.
SkinJect trial clearance gives Medicus Pharma a regulatory win as Nasdaq pressure builds
Medicus Pharma gains FDA clearance for its SkinJect Gorlin syndrome trial as stricter endpoints, secured debt and Nasdaq risks shape the outlook.